Volume 5 Issue 3
Jul.  2014
Turn off MathJax
Article Contents
Wen-ze WANG, Guo-tao MA, Yu XIAO, Zhi-yong LIANG, Wei-zhen LOU, Ji LI, Da-chun ZHAO, Huan-wen WU, Tong-hua LIU. Different Expressions of Bcl-2 and Vascular Endothelial Growth Factor Receptor-3 in Intravenous Leiomyomatosis and Classical Leiomyoma[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(3): 297-301. doi: 10.3969/j.issn.1674-9081.2014.03.010
Citation: Wen-ze WANG, Guo-tao MA, Yu XIAO, Zhi-yong LIANG, Wei-zhen LOU, Ji LI, Da-chun ZHAO, Huan-wen WU, Tong-hua LIU. Different Expressions of Bcl-2 and Vascular Endothelial Growth Factor Receptor-3 in Intravenous Leiomyomatosis and Classical Leiomyoma[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(3): 297-301. doi: 10.3969/j.issn.1674-9081.2014.03.010

Different Expressions of Bcl-2 and Vascular Endothelial Growth Factor Receptor-3 in Intravenous Leiomyomatosis and Classical Leiomyoma

doi: 10.3969/j.issn.1674-9081.2014.03.010
More Information
  • Corresponding author: LIU Tong-hua Tel: 010-69159361, E-mail:liuth_pumch@yahoo.com
  • Received Date: 2014-05-09
  • Publish Date: 2014-07-30
  •   Objective  To explore the different expressions of bcl-2 and vascular endothelial growth factor receptor-3 (VEGFR-3) in intravenous leiomyomatosis (IVL) and classical leiomyoma (LM).  Methods  We retrospectively reviewed the pathology of 20 cases of IVL, matching with 10 cases of LM. The bcl-2 and VEGFR-3 immunohistochemical staining was performed in the slides from all cases, and the results were compared between the IVL group and LM group.  Results  In the IVL group, all the 20 cases showed moderate to strong bcl-2 immunohistochemical staining. Meanwhile, 19 cases showed moderate to strong VEGFR-3 immunohistochemical staining, while 1 case was negative. In the LM group, all 10 cases showed weak to moderate bcl-2 immunohistochemical staining and negative VEGFR-3 staining.  Conclusions  Both bcl-2 and VEGFR-3 are highly expressed in IVL; in particular, the expression of VEGFR-3 is dramatically different between IVL and LM. This indicates IVL and LM have different molecular alterations, which may play important roles in the pathogenesis and development of IVL.
  • loading
  • [1] Islam MS, Protic O, Giannubilo SR, et al. Uterine leiomyoma:available medical treatments and new possible therapeutic options[J]. J Clin Endocrinol Metab, 2013, 98:921-934. doi:  10.1210/jc.2012-3237
    [2] Du J, Zhao X, Guo D, et al. Intravenous leiomyomatosis of the uterus:a clinicopathologic study of 18 cases, with emphasis on early diagnosis and appropriate treatment strategies[J]. Hum Pathol, 2011, 42:1240-1246. doi:  10.1016/j.humpath.2010.10.015
    [3] 赵大春, 田庄, 梁智勇, 等.静脉内平滑肌瘤病的临床病理[J].协和医学杂志, 2012, 3:51-55. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhyx201201012
    [4] 古聪敏, 余美融, 林汉良.子宫静脉内平滑肌瘤病临床病理及免疫表型分析[J].诊断病理学杂志, 2009, 16:198-200. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zdblxzz200903011
    [5] Karmon AE, Cardozo ER, Rueda BR, et al. MicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention?[J]. Hum Reprod Update, 2014, doi: 10.1093/humupd/dmu0171.
    [6] Zhu Y, Xie SW, Zhang JF, et al. Involvement of Bcl-2, Src, and ERalpha in gossypol-mediated growth inhibition and apoptosis in human uterine leiomyoma and myometrial cells[J]. Acta Pharmacol Sin, 2010, 31:1593-1603. doi:  10.1038/aps.2010.153
    [7] Bodner K, Bodner-Adler B, Kimberger O, et al. Bcl-2 receptor expression in patients with uterine smooth muscle tumors:an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma[J]. J Soc Gynecol Investig, 2004, 11:187-191. doi:  10.1016/j.jsgi.2003.10.003
    [8] Beierle EA, Ma X, Stewart JE, et al. Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines[J]. Mol Carcinog, 2014, 53:230-242. doi:  10.1002/mc.21969
    [9] Decio A, Taraboletti G, Patton V, et al. Vascular endothelial growth factor C promotes ovarian carcinoma progression through paracrine and autocrine mechanisms[J]. Am J Pathol, 2014, 184:1050-1061. doi:  10.1016/j.ajpath.2013.12.030
    [10] Martins SF, Garcia EA, Luz MA, et al. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer[J]. Cancer Genomics Proteomics, 2013, 10:55-67. http://europepmc.org/abstract/MED/23603341
    [11] Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, et al. Vascular endothelial growth factor receptors 1, 3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis-correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met[J]. Tumour Biol, 2013, 34:2109-2117. doi:  10.1007/s13277-013-0776-1
    [12] Eklund L, Bry M, Alitalo K. Mouse models for studying angiogenesis and lymphangiogenesis in cancer[J]. Mol Oncol, 2013, 7:259-282. doi:  10.1016/j.molonc.2013.02.007
    [13] Akl H, Vervloessem T, Kiviluoto S, et al. A dual role for the anti-apoptotic Bcl-2 protein in cancer: Mitochondria versus endoplasmic reticulum[J]. Biochim Biophys Acta, 2014, doi: 10.1016/j.bbamcr.2014.04.017.
    [14] Greenberg EF, Lavik AR, Distelhorst CW. Bcl-2 regulation of the inositol 1, 4, 5-trisphosphate receptor and calcium signaling in normal and malignant lymphocytes: Potential new target for cancer treatment[J]. Biochim Biophys Acta, 2014, doi: 10.1016/j.bbamcr.2014.03.008.
    [15] Chen MJ, Peng Y, Yang YS, et al. Increased hyaluronan and CD44 expressions in intravenous leiomyomatosis[J]. Acta Obstet Gynecol Scand, 2005, 84:322-328. doi:  10.1111/j.0001-6349.2005.00707.x
    [16] Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors[J]. Cold Spring Harb Perspect Med, 2012, 2:a6502. doi:  10.1101/cshperspect.a006502
    [17] Welti J, Loges S, Dimmeler S, et al. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer[J]. J Clin Invest, 2013, 123:3190-3200. doi:  10.1172/JCI70212
    [18] Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy[J]. Biol Pharm Bull, 2011, 34:1785-1788. doi:  10.1248/bpb.34.1785
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Article Metrics

    Article views (147) PDF downloads(4) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return